Fortis Healthcare Limited
Fortis Healthcare Limited (FORTIS.NS) Stock Competitors & Peer Comparison
See (FORTIS.NS) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Care Facilities Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| FORTIS.NS | ₹906.60 | -1.56% | 694.3B | 72.36 | ₹12.71 | +0.11% |
| APOLLOHOSP.BO | ₹7,587.90 | -0.30% | 1.1T | 61.33 | ₹125.44 | +0.26% |
| APOLLOHOSP.NS | ₹7,592.50 | -0.30% | 1.1T | 61.78 | ₹124.52 | +0.26% |
| MAXHEALTH.NS | ₹1,081.45 | -0.59% | 1.1T | 74.78 | ₹14.49 | +0.14% |
| MAXHEALTH.BO | ₹1,081.05 | -0.65% | 1.1T | 74.29 | ₹14.58 | +0.14% |
| FORTIS.BO | ₹906.60 | -1.47% | 694.2B | 72.41 | ₹12.70 | +0.11% |
| NH.NS | ₹1,837.60 | +0.58% | 379.7B | 48.73 | ₹38.37 | +0.24% |
| NH.BO | ₹1,836.15 | +0.47% | 379.5B | 44.96 | ₹41.56 | +0.24% |
| ASTERDM.BO | ₹635.90 | +0.78% | 334.2B | 100.70 | ₹6.42 | +0.77% |
| ASTERDM.NS | ₹636.80 | +0.95% | 334B | 100.47 | ₹6.43 | +0.77% |
Stock Comparison
FORTIS.NS vs APOLLOHOSP.BO Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, APOLLOHOSP.BO has a market cap of 1.1T. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while APOLLOHOSP.BO trades at ₹7,587.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas APOLLOHOSP.BO's P/E ratio is 61.33. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to APOLLOHOSP.BO's ROE of +0.21%. Regarding short-term risk, FORTIS.NS is more volatile compared to APOLLOHOSP.BO. This indicates potentially higher risk in terms of short-term price fluctuations for FORTIS.NS.Check APOLLOHOSP.BO's competition here
FORTIS.NS vs APOLLOHOSP.NS Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, APOLLOHOSP.NS has a market cap of 1.1T. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while APOLLOHOSP.NS trades at ₹7,592.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas APOLLOHOSP.NS's P/E ratio is 61.78. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to APOLLOHOSP.NS's ROE of +0.21%. Regarding short-term risk, FORTIS.NS is more volatile compared to APOLLOHOSP.NS. This indicates potentially higher risk in terms of short-term price fluctuations for FORTIS.NS.Check APOLLOHOSP.NS's competition here
FORTIS.NS vs MAXHEALTH.NS Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, MAXHEALTH.NS has a market cap of 1.1T. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while MAXHEALTH.NS trades at ₹1,081.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas MAXHEALTH.NS's P/E ratio is 74.78. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to MAXHEALTH.NS's ROE of +0.15%. Regarding short-term risk, FORTIS.NS is more volatile compared to MAXHEALTH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for FORTIS.NS.Check MAXHEALTH.NS's competition here
FORTIS.NS vs MAXHEALTH.BO Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, MAXHEALTH.BO has a market cap of 1.1T. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while MAXHEALTH.BO trades at ₹1,081.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas MAXHEALTH.BO's P/E ratio is 74.29. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to MAXHEALTH.BO's ROE of +0.15%. Regarding short-term risk, FORTIS.NS is more volatile compared to MAXHEALTH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for FORTIS.NS.Check MAXHEALTH.BO's competition here
FORTIS.NS vs FORTIS.BO Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, FORTIS.BO has a market cap of 694.2B. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while FORTIS.BO trades at ₹906.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas FORTIS.BO's P/E ratio is 72.41. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to FORTIS.BO's ROE of +0.11%. Regarding short-term risk, FORTIS.NS is less volatile compared to FORTIS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check FORTIS.BO's competition here
FORTIS.NS vs NH.NS Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, NH.NS has a market cap of 379.7B. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while NH.NS trades at ₹1,837.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas NH.NS's P/E ratio is 48.73. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to NH.NS's ROE of +0.21%. Regarding short-term risk, FORTIS.NS is more volatile compared to NH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for FORTIS.NS.Check NH.NS's competition here
FORTIS.NS vs NH.BO Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, NH.BO has a market cap of 379.5B. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while NH.BO trades at ₹1,836.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas NH.BO's P/E ratio is 44.96. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to NH.BO's ROE of +0.21%. Regarding short-term risk, FORTIS.NS is more volatile compared to NH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for FORTIS.NS.Check NH.BO's competition here
FORTIS.NS vs ASTERDM.BO Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, ASTERDM.BO has a market cap of 334.2B. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while ASTERDM.BO trades at ₹635.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas ASTERDM.BO's P/E ratio is 100.70. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to ASTERDM.BO's ROE of +0.09%. Regarding short-term risk, FORTIS.NS is less volatile compared to ASTERDM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check ASTERDM.BO's competition here
FORTIS.NS vs ASTERDM.NS Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, ASTERDM.NS has a market cap of 334B. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while ASTERDM.NS trades at ₹636.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas ASTERDM.NS's P/E ratio is 100.47. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to ASTERDM.NS's ROE of +0.09%. Regarding short-term risk, FORTIS.NS is less volatile compared to ASTERDM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check ASTERDM.NS's competition here
FORTIS.NS vs MEDANTA.NS Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, MEDANTA.NS has a market cap of 313.4B. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while MEDANTA.NS trades at ₹1,139.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas MEDANTA.NS's P/E ratio is 61.05. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to MEDANTA.NS's ROE of +0.15%. Regarding short-term risk, FORTIS.NS is less volatile compared to MEDANTA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check MEDANTA.NS's competition here
FORTIS.NS vs MEDANTA.BO Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, MEDANTA.BO has a market cap of 313.1B. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while MEDANTA.BO trades at ₹1,139.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas MEDANTA.BO's P/E ratio is 61.03. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to MEDANTA.BO's ROE of +0.15%. Regarding short-term risk, FORTIS.NS is less volatile compared to MEDANTA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check MEDANTA.BO's competition here
FORTIS.NS vs KIMS.BO Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, KIMS.BO has a market cap of 287.2B. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while KIMS.BO trades at ₹699.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas KIMS.BO's P/E ratio is 95.95. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to KIMS.BO's ROE of +0.13%. Regarding short-term risk, FORTIS.NS is less volatile compared to KIMS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check KIMS.BO's competition here
FORTIS.NS vs KIMS.NS Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, KIMS.NS has a market cap of 287.1B. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while KIMS.NS trades at ₹700.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas KIMS.NS's P/E ratio is 95.79. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to KIMS.NS's ROE of +0.13%. Regarding short-term risk, FORTIS.NS is less volatile compared to KIMS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check KIMS.NS's competition here
FORTIS.NS vs RAINBOW.NS Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, RAINBOW.NS has a market cap of 123.6B. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while RAINBOW.NS trades at ₹1,201.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas RAINBOW.NS's P/E ratio is 48.18. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to RAINBOW.NS's ROE of +0.18%. Regarding short-term risk, FORTIS.NS is less volatile compared to RAINBOW.NS. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check RAINBOW.NS's competition here
FORTIS.NS vs RAINBOW.BO Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, RAINBOW.BO has a market cap of 123.5B. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while RAINBOW.BO trades at ₹1,203.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas RAINBOW.BO's P/E ratio is 48.58. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to RAINBOW.BO's ROE of +0.18%. Regarding short-term risk, FORTIS.NS is less volatile compared to RAINBOW.BO. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check RAINBOW.BO's competition here
FORTIS.NS vs HCG.NS Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, HCG.NS has a market cap of 83.6B. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while HCG.NS trades at ₹594.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas HCG.NS's P/E ratio is 439.04. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to HCG.NS's ROE of +0.02%. Regarding short-term risk, FORTIS.NS is more volatile compared to HCG.NS. This indicates potentially higher risk in terms of short-term price fluctuations for FORTIS.NS.Check HCG.NS's competition here
FORTIS.NS vs HCG.BO Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, HCG.BO has a market cap of 83.4B. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while HCG.BO trades at ₹594.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas HCG.BO's P/E ratio is 438.15. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to HCG.BO's ROE of +0.02%. Regarding short-term risk, FORTIS.NS is more volatile compared to HCG.BO. This indicates potentially higher risk in terms of short-term price fluctuations for FORTIS.NS.Check HCG.BO's competition here
FORTIS.NS vs JLHL.BO Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, JLHL.BO has a market cap of 80.9B. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while JLHL.BO trades at ₹1,233.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas JLHL.BO's P/E ratio is 42.75. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to JLHL.BO's ROE of +0.14%. Regarding short-term risk, FORTIS.NS is less volatile compared to JLHL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check JLHL.BO's competition here
FORTIS.NS vs JLHL.NS Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, JLHL.NS has a market cap of 80.5B. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while JLHL.NS trades at ₹1,232.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas JLHL.NS's P/E ratio is 42.57. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to JLHL.NS's ROE of +0.14%. Regarding short-term risk, FORTIS.NS is more volatile compared to JLHL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for FORTIS.NS.Check JLHL.NS's competition here
FORTIS.NS vs YATHARTH.NS Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, YATHARTH.NS has a market cap of 69.7B. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while YATHARTH.NS trades at ₹694.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas YATHARTH.NS's P/E ratio is 41.50. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to YATHARTH.NS's ROE of +0.11%. Regarding short-term risk, FORTIS.NS is less volatile compared to YATHARTH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check YATHARTH.NS's competition here
FORTIS.NS vs YATHARTH.BO Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, YATHARTH.BO has a market cap of 69.6B. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while YATHARTH.BO trades at ₹695.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas YATHARTH.BO's P/E ratio is 41.58. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to YATHARTH.BO's ROE of +0.11%. Regarding short-term risk, FORTIS.NS is less volatile compared to YATHARTH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check YATHARTH.BO's competition here
FORTIS.NS vs KOVAI.BO Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, KOVAI.BO has a market cap of 57B. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while KOVAI.BO trades at ₹5,309.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas KOVAI.BO's P/E ratio is 24.17. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to KOVAI.BO's ROE of +0.22%. Regarding short-term risk, FORTIS.NS is less volatile compared to KOVAI.BO. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check KOVAI.BO's competition here
FORTIS.NS vs ARTEMISMED.BO Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, ARTEMISMED.BO has a market cap of 38.1B. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while ARTEMISMED.BO trades at ₹238.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas ARTEMISMED.BO's P/E ratio is N/A. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to ARTEMISMED.BO's ROE of +0.11%. Regarding short-term risk, FORTIS.NS is less volatile compared to ARTEMISMED.BO. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check ARTEMISMED.BO's competition here
FORTIS.NS vs ARTEMISMED.NS Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, ARTEMISMED.NS has a market cap of 38B. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while ARTEMISMED.NS trades at ₹239.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas ARTEMISMED.NS's P/E ratio is 105.28. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to ARTEMISMED.NS's ROE of +0.11%. Regarding short-term risk, FORTIS.NS is less volatile compared to ARTEMISMED.NS. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check ARTEMISMED.NS's competition here
FORTIS.NS vs INDRAMEDCO.NS Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, INDRAMEDCO.NS has a market cap of 37.5B. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while INDRAMEDCO.NS trades at ₹405.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas INDRAMEDCO.NS's P/E ratio is 20.49. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to INDRAMEDCO.NS's ROE of +0.31%. Regarding short-term risk, FORTIS.NS is less volatile compared to INDRAMEDCO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check INDRAMEDCO.NS's competition here
FORTIS.NS vs INDRAMEDCO.BO Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, INDRAMEDCO.BO has a market cap of 37.4B. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while INDRAMEDCO.BO trades at ₹406.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas INDRAMEDCO.BO's P/E ratio is 20.47. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to INDRAMEDCO.BO's ROE of +0.31%. Regarding short-term risk, FORTIS.NS is less volatile compared to INDRAMEDCO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check INDRAMEDCO.BO's competition here
FORTIS.NS vs KOVAI.NS Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, KOVAI.NS has a market cap of 35.3B. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while KOVAI.NS trades at ₹2,581.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas KOVAI.NS's P/E ratio is 20.74. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to KOVAI.NS's ROE of +0.22%. Regarding short-term risk, FORTIS.NS is less volatile compared to KOVAI.NS. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check KOVAI.NS's competition here
FORTIS.NS vs DRAGARWQ.BO Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, DRAGARWQ.BO has a market cap of 21.7B. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while DRAGARWQ.BO trades at ₹4,771.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas DRAGARWQ.BO's P/E ratio is 31.35. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to DRAGARWQ.BO's ROE of +0.30%. Regarding short-term risk, FORTIS.NS is less volatile compared to DRAGARWQ.BO. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check DRAGARWQ.BO's competition here
FORTIS.NS vs SHALBY.NS Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, SHALBY.NS has a market cap of 16.5B. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while SHALBY.NS trades at ₹156.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas SHALBY.NS's P/E ratio is 196.79. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to SHALBY.NS's ROE of +0.01%. Regarding short-term risk, FORTIS.NS is less volatile compared to SHALBY.NS. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check SHALBY.NS's competition here
FORTIS.NS vs SHALBY.BO Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, SHALBY.BO has a market cap of 16.5B. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while SHALBY.BO trades at ₹156.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas SHALBY.BO's P/E ratio is 196.60. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to SHALBY.BO's ROE of +0.01%. Regarding short-term risk, FORTIS.NS is less volatile compared to SHALBY.BO. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check SHALBY.BO's competition here
FORTIS.NS vs KMCSHIL.BO Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, KMCSHIL.BO has a market cap of 13.4B. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while KMCSHIL.BO trades at ₹82.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas KMCSHIL.BO's P/E ratio is 36.81. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to KMCSHIL.BO's ROE of +0.22%. Regarding short-term risk, FORTIS.NS is less volatile compared to KMCSHIL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check KMCSHIL.BO's competition here
FORTIS.NS vs MAXINDIA.BO Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, MAXINDIA.BO has a market cap of 9.2B. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while MAXINDIA.BO trades at ₹213.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas MAXINDIA.BO's P/E ratio is -3560.83. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to MAXINDIA.BO's ROE of +0.15%. Regarding short-term risk, FORTIS.NS is less volatile compared to MAXINDIA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check MAXINDIA.BO's competition here
FORTIS.NS vs MAXIND.NS Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, MAXIND.NS has a market cap of 8.3B. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while MAXIND.NS trades at ₹157.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas MAXIND.NS's P/E ratio is -5.54. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to MAXIND.NS's ROE of -0.36%. Regarding short-term risk, FORTIS.NS is less volatile compared to MAXIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check MAXIND.NS's competition here
FORTIS.NS vs ASARFI.BO Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, ASARFI.BO has a market cap of 3.2B. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while ASARFI.BO trades at ₹169.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas ASARFI.BO's P/E ratio is 19.82. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to ASARFI.BO's ROE of +0.14%. Regarding short-term risk, FORTIS.NS is less volatile compared to ASARFI.BO. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check ASARFI.BO's competition here
FORTIS.NS vs LOTUSEYE.NS Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, LOTUSEYE.NS has a market cap of 2.3B. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while LOTUSEYE.NS trades at ₹123.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas LOTUSEYE.NS's P/E ratio is 349.91. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to LOTUSEYE.NS's ROE of +0.01%. Regarding short-term risk, FORTIS.NS is less volatile compared to LOTUSEYE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check LOTUSEYE.NS's competition here
FORTIS.NS vs LOTUSEYE.BO Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, LOTUSEYE.BO has a market cap of 2.3B. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while LOTUSEYE.BO trades at ₹123.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas LOTUSEYE.BO's P/E ratio is 348.59. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to LOTUSEYE.BO's ROE of +0.01%. Regarding short-term risk, FORTIS.NS is less volatile compared to LOTUSEYE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check LOTUSEYE.BO's competition here
FORTIS.NS vs AASHKA.BO Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, AASHKA.BO has a market cap of 1.9B. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while AASHKA.BO trades at ₹76.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas AASHKA.BO's P/E ratio is 76.92. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to AASHKA.BO's ROE of +0.02%. Regarding short-term risk, FORTIS.NS is more volatile compared to AASHKA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for FORTIS.NS.Check AASHKA.BO's competition here
FORTIS.NS vs LEHIL.BO Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, LEHIL.BO has a market cap of 1.9B. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while LEHIL.BO trades at ₹89.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas LEHIL.BO's P/E ratio is -315.00. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to LEHIL.BO's ROE of +0.01%. Regarding short-term risk, FORTIS.NS is less volatile compared to LEHIL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check LEHIL.BO's competition here
FORTIS.NS vs JSTL.BO Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, JSTL.BO has a market cap of 1.1B. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while JSTL.BO trades at ₹69.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas JSTL.BO's P/E ratio is -53.09. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to JSTL.BO's ROE of -0.06%. Regarding short-term risk, FORTIS.NS is less volatile compared to JSTL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check JSTL.BO's competition here
FORTIS.NS vs FORTISMLR.BO Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, FORTISMLR.BO has a market cap of 997.8M. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while FORTISMLR.BO trades at ₹55.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas FORTISMLR.BO's P/E ratio is 22.00. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to FORTISMLR.BO's ROE of +0.15%. Regarding short-term risk, FORTIS.NS is more volatile compared to FORTISMLR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for FORTIS.NS.Check FORTISMLR.BO's competition here
FORTIS.NS vs ASPIRA.BO Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, ASPIRA.BO has a market cap of 616M. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while ASPIRA.BO trades at ₹60.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas ASPIRA.BO's P/E ratio is 43.37. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to ASPIRA.BO's ROE of +0.11%. Regarding short-term risk, FORTIS.NS is more volatile compared to ASPIRA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for FORTIS.NS.Check ASPIRA.BO's competition here
FORTIS.NS vs NGIND.BO Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, NGIND.BO has a market cap of 476.9M. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while NGIND.BO trades at ₹135.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas NGIND.BO's P/E ratio is 9.74. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to NGIND.BO's ROE of -0.04%. Regarding short-term risk, FORTIS.NS is more volatile compared to NGIND.BO. This indicates potentially higher risk in terms of short-term price fluctuations for FORTIS.NS.Check NGIND.BO's competition here
FORTIS.NS vs MEDINOV.BO Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, MEDINOV.BO has a market cap of 433.7M. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while MEDINOV.BO trades at ₹43.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas MEDINOV.BO's P/E ratio is 20.21. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to MEDINOV.BO's ROE of -1.80%. Regarding short-term risk, FORTIS.NS is less volatile compared to MEDINOV.BO. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check MEDINOV.BO's competition here
FORTIS.NS vs CMMHOSP.BO Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, CMMHOSP.BO has a market cap of 310M. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while CMMHOSP.BO trades at ₹44.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas CMMHOSP.BO's P/E ratio is -31.68. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to CMMHOSP.BO's ROE of +0.42%. Regarding short-term risk, FORTIS.NS is less volatile compared to CMMHOSP.BO. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check CMMHOSP.BO's competition here
FORTIS.NS vs TEJNAKSH.BO Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, TEJNAKSH.BO has a market cap of 281.7M. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while TEJNAKSH.BO trades at ₹13.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas TEJNAKSH.BO's P/E ratio is 20.40. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to TEJNAKSH.BO's ROE of +0.05%. Regarding short-term risk, FORTIS.NS is less volatile compared to TEJNAKSH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check TEJNAKSH.BO's competition here
FORTIS.NS vs SML.BO Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, SML.BO has a market cap of 267.4M. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while SML.BO trades at ₹69.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas SML.BO's P/E ratio is -26.79. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to SML.BO's ROE of -1.02%. Regarding short-term risk, FORTIS.NS is more volatile compared to SML.BO. This indicates potentially higher risk in terms of short-term price fluctuations for FORTIS.NS.Check SML.BO's competition here
FORTIS.NS vs KKSHL.BO Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, KKSHL.BO has a market cap of 245.1M. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while KKSHL.BO trades at ₹36.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas KKSHL.BO's P/E ratio is -23.84. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to KKSHL.BO's ROE of -0.02%. Regarding short-term risk, FORTIS.NS is more volatile compared to KKSHL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for FORTIS.NS.Check KKSHL.BO's competition here
FORTIS.NS vs GLHRL.BO Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, GLHRL.BO has a market cap of 187.4M. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while GLHRL.BO trades at ₹16.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas GLHRL.BO's P/E ratio is -7.56. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to GLHRL.BO's ROE of +0.01%. Regarding short-term risk, FORTIS.NS is more volatile compared to GLHRL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for FORTIS.NS.Check GLHRL.BO's competition here
FORTIS.NS vs FAMILYCARE.BO Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, FAMILYCARE.BO has a market cap of 183.7M. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while FAMILYCARE.BO trades at ₹3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas FAMILYCARE.BO's P/E ratio is -3.51. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to FAMILYCARE.BO's ROE of -0.43%. Regarding short-term risk, FORTIS.NS is less volatile compared to FAMILYCARE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check FAMILYCARE.BO's competition here
FORTIS.NS vs ZDHJERK.BO Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, ZDHJERK.BO has a market cap of 108.6M. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while ZDHJERK.BO trades at ₹24.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas ZDHJERK.BO's P/E ratio is 40.77. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to ZDHJERK.BO's ROE of +0.01%. Regarding short-term risk, FORTIS.NS is less volatile compared to ZDHJERK.BO. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check ZDHJERK.BO's competition here
FORTIS.NS vs LOOKS.BO Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, LOOKS.BO has a market cap of 105.2M. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while LOOKS.BO trades at ₹9.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas LOOKS.BO's P/E ratio is 50.10. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to LOOKS.BO's ROE of +0.01%. Regarding short-term risk, FORTIS.NS is less volatile compared to LOOKS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check LOOKS.BO's competition here
FORTIS.NS vs GIANLIFE.BO Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, GIANLIFE.BO has a market cap of 90.5M. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while GIANLIFE.BO trades at ₹9.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas GIANLIFE.BO's P/E ratio is -12.50. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to GIANLIFE.BO's ROE of -0.05%. Regarding short-term risk, FORTIS.NS is less volatile compared to GIANLIFE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check GIANLIFE.BO's competition here
FORTIS.NS vs DLCL.BO Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, DLCL.BO has a market cap of 72.4M. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while DLCL.BO trades at ₹16.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas DLCL.BO's P/E ratio is 21.70. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to DLCL.BO's ROE of +0.04%. Regarding short-term risk, FORTIS.NS is less volatile compared to DLCL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check DLCL.BO's competition here
FORTIS.NS vs NEPHROCARE-ST.NS Comparison February 2026
FORTIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FORTIS.NS stands at 694.3B. In comparison, NEPHROCARE-ST.NS has a market cap of 0. Regarding current trading prices, FORTIS.NS is priced at ₹906.60, while NEPHROCARE-ST.NS trades at ₹128.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FORTIS.NS currently has a P/E ratio of 72.36, whereas NEPHROCARE-ST.NS's P/E ratio is N/A. In terms of profitability, FORTIS.NS's ROE is +0.11%, compared to NEPHROCARE-ST.NS's ROE of N/A. Regarding short-term risk, FORTIS.NS is less volatile compared to NEPHROCARE-ST.NS. This indicates potentially lower risk in terms of short-term price fluctuations for FORTIS.NS.Check NEPHROCARE-ST.NS's competition here